Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer

NCT03674567 is registered in ClinicalTrials.gov with RAPT Therapeutics, Inc., a member of the GSK plc group of companies as lead sponsor.

NCT NCT03674567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03674567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Phase
Phase 1/2
Overall status
Completed
Start date
September 25, 2018
Completion date
December 31, 2024
Enrollment
323 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer